(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 June 2006 (01.06.2006)

PCT

(10) International Publication Number
WO 2006/056884 A1

(51) International Patent Classification:
C07D 207/14 (2006.01) *A61K 31/40* (2006.01)

(21) International Application Number:
PCT/IB2005/003643

(22) International Filing Date:
18 November 2005 (18.11.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0425766.3 23 November 2004 (23.11.2004) GB

(71) Applicant *(for GB only)*: **PFIZER LIMITED** [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(71) Applicant *(for all designated States except GB, US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FISH, Paul, Vincent** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **RYCKMANS, Thomas** [BE/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **STOBIE, Alan** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **WAKENHUT, Florian** [FR/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **WHITLOCK, Gavin, Alistair** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(74) Agent: **DROUIN, Stephane**; Pfizer Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** N- [(3S)- PYRROLIDIN-3-YL]- BENZAMIDE DERIVATIVES AS MONOAMINE RE-UPTAKE INHIBITORS



(57) **Abstract:** A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein: R^1, R^2, R^3 and R^{20} are each independently H, CI, Br, F, I, CF_3, OCF_3, Me or Et; R^4 is het or C_{3-7} cycloalkyl optionally substituted by C_{1-4} alkyl, C_{1-4} alkoxy, alkoxyalkyl containing 2 to 4 carbon atoms or -S-(C_{1-4} alkyl); a is 0 or 1; and het is a non-aromatic 4-, 5- or 6- membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to a 5- or 6- membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom, wherein the het group is optionally substituted by at least one substituent independently selected from C_{1-8}alkyl, C_{1-8}alkoxy, OH, halo, CF_3, OCF_3, SCF_3, hydroxy-C_{1-6}alkyl, C_{1-4} alkoxy-C_{1-6}alkyl and C_{1-4} alkyl-S-C_{1-4}alkyl; provided that at least one of R^1, R^2 and R^3 are other than H. The compounds of the invention exhibit activity as both serotonin and noradrenaline re-uptake inhibitors and therefore have utility in a variety of therapeutic areas, for example urinary incontinence.

WO 2006/056884 A1